Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07374848 · ClinicalTrials.gov registry record · Phase 1
Phase 1a/b Study of ZL-6201 Safety, PK, and Preliminary Efficacy in Sarcoma and Selected Tumors
A Phase 1 study of Solid Tumors and Sarcomas, sponsored by Zai Lab (Shanghai) Co..
- Recruiting
- Registry status
- Phase 1
- Development phase
- 180
- Enrollment target
- 2
- Study locations
NCT07374848: Recruiting Phase 1 study of Solid Tumors and Sarcomas, sponsored by Zai Lab (Shanghai) Co..
NCT07374848 is a Phase 1 study of Solid Tumors and Sarcomas that is actively recruiting participants, run by Zai Lab (Shanghai) Co.. The registered enrollment target is 180 participants, below the 283-participant average among 125 other Solid Tumors trials with a reported enrollment target (36% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07374848, a Phase 1 study of Solid Tumors and Sarcomas, is actively recruiting participants, sponsored by Zai Lab (Shanghai) Co..
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 180 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to evaluate the safety and tolerability of investigational study drug ZL-6201 for treating sarcoma and solid tumors cancer.
Primary Outcome
Number of subjects with dose limiting toxicities (DLTs) through dose escalation only.
Conditions Studied
Interventions
- DRUG ZL-6201
Study Locations (2)
Florida
- Zai Lab Site 02026 - Sarasota
Virginia
- Zai Lab Site 02006 - Fairfax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2026-03 |
| Est. Completion | 2029-09 |
| Phase | Phase 1 |
What NCT07374848 shows while recruiting
NCT07374848 is an interventional study that assigns participants to a tested intervention. The registered 180 participants enrollment target is mid-sized for trials with a published cap, below the 283-participant average among 125 other Solid Tumors trials with a reported enrollment target (36% lower).
The record links to 2 conditions, with Solid Tumors appearing as the primary indexed condition, and to 1 intervention - of which ZL-6201 is the first listed.
NCT07374848 reports a single indexed study location in Florida, Virginia.
Frequently Asked Questions
What is clinical trial NCT07374848 about?
NCT07374848 is a clinical study titled "Phase 1a/b Study of ZL-6201 Safety, PK, and Preliminary Efficacy in Sarcoma and Selected Tumors". The purpose of this study is to evaluate the safety and tolerability of investigational study drug ZL-6201 for treating sarcoma and solid tumors cancer.
What is the current status of trial NCT07374848?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 180 participants. The study started on 2026-03. Estimated completion is 2029-09.
What conditions does trial NCT07374848 study?
This clinical trial studies the following conditions: Solid Tumors, Sarcomas.
What interventions are being tested in trial NCT07374848?
The interventions under investigation include: ZL-6201 (DRUG).
Who is sponsoring clinical trial NCT07374848?
This trial is sponsored by Zai Lab (Shanghai) Co., which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07374848 being conducted?
This trial has 2 study locations across Florida, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07374848's enrollment target sits among peer trials
180 34th of 125 higher than 92 of 125 other Solid Tumors trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Solid Tumors trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A First-in-Human Study of BG-C0902 Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of INCB123667 in Subjects With Advanced Solid Tumors
RECRUITING · Phase 1
-
JAB-2485 Activity in Adult Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
RECRUITING · Phase 1
-
Study of AUBE00 in Patients With Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01558804 · 180 participants
GRoup A StrePtococcus
- NCT02932176 · 180 participants
Machine Learning for Handheld Vascular Studies
- NCT03384563 · 180 participants · Phase 4
Effect of Dexmedetomidine on the Minimum Alveolar Concentration of Sevoflurane
- NCT03423628 · 180 participants · Phase 1
A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia